Relmada Therapeutics (RLMD) Assets (2012 - 2026)
Relmada Therapeutics (RLMD) reported Assets of $235.4 million for Q1 2026, up 750.32% year-over-year from $27.7 million in Q1 2025, and up 150.38% on a QoQ basis from $94.0 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Assets data on file, last reported at $235.4 million in Q1 2026.
- Quarterly Assets rose 750.32% year-over-year to $235.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.4 million (up 750.32% YoY) and the FY2025 annual result came in at $94.0 million, up 105.17% from the prior year.
- Assets rose to $235.4 million in Q1 2026 per RLMD's latest filing, from $94.0 million in the prior quarter.
- Across five years, Assets topped out at $235.4 million in Q1 2026 and bottomed at $14.9 million in Q3 2025.
- The 5-year median for Assets is $97.6 million (2023), against an average of $111.5 million.
- The widest annual swing landed in 2025, when Assets slumped 73.3%; it then jumped 750.32% in 2026.
- Tracing RLMD's Assets over 5 years: stood at $152.9 million in 2022, then plunged by 36.2% to $97.6 million in 2023, then sank by 53.03% to $45.8 million in 2024, then surged by 105.17% to $94.0 million in 2025, then surged by 150.38% to $235.4 million in 2026.
- Per Business Quant, the three latest RLMD Assets figures stand at $235.4 million (Q1 2026), $94.0 million (Q4 2025), and $14.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 235.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 235.36 Mn |
| Dec 31, 2025 | 94.00 Mn |
| Sep 30, 2025 | 14.88 Mn |
| Jun 30, 2025 | 21.12 Mn |
| Mar 31, 2025 | 27.68 Mn |
| Dec 31, 2024 | 45.82 Mn |
| Sep 30, 2024 | 55.72 Mn |
| Jun 30, 2024 | 71.03 Mn |
| Mar 31, 2024 | 84.41 Mn |
| Dec 31, 2023 | 97.55 Mn |
| Sep 30, 2023 | 109.15 Mn |
| Jun 30, 2023 | 122.04 Mn |
| Mar 31, 2023 | 135.57 Mn |
| Dec 31, 2022 | 152.91 Mn |
| Sep 30, 2022 | 187.12 Mn |
| Jun 30, 2022 | 215.77 Mn |
| Mar 31, 2022 | 225.81 Mn |
| Dec 31, 2021 | 223.33 Mn |
| Sep 30, 2021 | 90.93 Mn |
| Jun 30, 2021 | 110.77 Mn |
| Mar 31, 2021 | 103.87 Mn |
| Dec 31, 2020 | 118.19 Mn |
| Sep 30, 2020 | 125.60 Mn |
| Jun 30, 2020 | 134.56 Mn |
| Mar 31, 2020 | 115.42 Mn |
| Dec 31, 2019 | 117.14 Mn |
| Sep 30, 2019 | 8.51 Mn |
| Jun 30, 2019 | 10.22 Mn |
| Mar 31, 2019 | 2.60 Mn |
| Dec 31, 2018 | 3.30 Mn |
| Sep 30, 2018 | 1.56 Mn |
| Jun 30, 2018 | 3.05 Mn |
| Mar 31, 2018 | 4.80 Mn |
| Dec 31, 2017 | 6.57 Mn |
| Sep 30, 2017 | 5.61 Mn |
| Jun 30, 2017 | 2.84 Mn |
| Mar 31, 2017 | 4.17 Mn |
| Dec 31, 2016 | 6.23 Mn |
| Sep 30, 2016 | 7.92 Mn |
| Jun 30, 2016 | 10.24 Mn |
| Mar 31, 2016 | 12.72 Mn |
| Dec 31, 2015 | 16.60 Mn |
| Sep 30, 2015 | 20.48 Mn |
| Jun 30, 2015 | 24.39 Mn |
| Mar 31, 2015 | 27.85 Mn |
| Dec 31, 2014 | 32.79 Mn |
| Sep 30, 2014 | 27.85 Mn |
| Jun 30, 2014 | 25.76 Mn |
| Nov 30, 2013 | 12,300.00 |
| Aug 31, 2013 | 20,009.00 |
| May 31, 2013 | 4,733.00 |
| Feb 28, 2013 | 10,194.00 |
| Aug 31, 2012 | 18,354.00 |